Healthcare systems remain fragmented, with disease-specific screening pathways requiring separate technologies, specialists, infrastructure and patient visits. Retinal diseases (diabetic retinopathy, glaucoma and AMD) require fundus imaging or OCT; cardiovascular screening involves ECG, echocardiography and laboratory tests; kidney disease requires laboratory-based assessments. Maternal screening needs haemoglobin, glucose, blood-pressure and Doppler tests. This fragmentation increases travel costs, waiting time and lost wages, making screening symptom-driven rather than preventive and delaying early detection. In India, over 20 million people risk vision loss from retinal diseases; 220 million face hypertension risk; over 80 million live with diabetes; and over 195 million are affected by cardiovascular and kidney diseases. Additionally, over 20 million women face pregnancy-related conditions, including preeclampsia, gestational diabetes and anaemia. This underscores the need for a low-cost, point-of-care platform enabling multi-disease screening through a single device and unified workflow.

The Problem
The Motivation
Remidio’s journey was shaped by personal loss, professional insight and a chance encounter. After losing his mother to a cardiac event, Anand Sivaraman, an IIT Kharagpur graduate with a PhD and postdoctoral research experience at MIT, returned to India with a renewed commitment to public health and technology-enabled prevention. During a 2010 train journey from Kochi to Bangalore, he met paediatric ophthalmologist Dr. Anand Vinekar, who highlighted the lack of affordable, portable imaging to detect retinopathy of prematurity and prevent avoidable blindness. Sivaraman recognised a wider gap: specialists spent considerable time identifying patients needing treatment. This inspired him to bring screening closer to communities through simple, portable, smartphone-based technologies, ultimately leading to Remidio’s founding and its mission to democratise preventive healthcare.
The Inclusive Innovation
Remidio’s MediosHI AI platform transforms a single retinal examination into a comprehensive, AI-assisted screening platform for both eye and systemic health. It is a portable, non-invasive retinal imaging platform that uses offline edge AI to screen for 10 diseases and health conditions through a single ~75-second eye examination at approximately ₹100. It covers three eye conditions—diabetic retinopathy (DR), glaucoma, and age-related macular degeneration (AMD)—and seven systemic health conditions: diabetes through HbA1c, hypertension, cardiovascular disease (CVD), chronic kidney disease (CKD), preeclampsia, anaemia, and gestational diabetes.
The Impact
Overall, Remidio has deployed 4,000+ devices worldwide, screening 16 million+ patients across 55+ countries. Its impact in expanding access to affordable, technology-enabled screening has gained global recognition, with Bill Gates spotlighting Remidio in an April 2026 Gates Notes article on preventing stillbirths and highlighting its retinal imaging technology for underserved maternal-health settings.